1. Indications and Usage
\nInsomnia:
\nIndicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and\/or sleep maintenance.
\n2. Dosage and Administration
\nRecommended Dosage:
\nAdults: 25 mg or 50 mg orally once nightly.
\nAdministration Instructions:
\nTake within 30 minutes before going to bed.
\nEnsure at least 7 hours remain before the planned time of awakening.
\nTaking with or immediately after a meal may delay the onset of sleep.
\nDose Modifications:
\nConcomitant use with moderate CYP3A4 inhibitors: The maximum recommended dose is 25 mg once nightly.
\nModerate hepatic impairment (Child-Pugh class B): The maximum recommended dose is 25 mg once nightly.
\nNote: Avoid use in patients with severe hepatic impairment (Child-Pugh class C).
\n3. Mechanism of Action
\nDual Orexin Receptor Antagonist (DORA):
\nDaridorexant is an orexin receptor antagonist.
\nPhysiological Effect:
\nIt binds with high affinity to orexin receptors OX1R and OX2R, blocking the binding of the wake-promoting neuropeptides orexin A and orexin B. By antagonizing orexin receptors, it suppresses the wake drive, thereby facilitating the transition to and maintenance of sleep.
\n4. Safety and Warnings
\nCentral Nervous System (CNS) Depressant Effects and Daytime Impairment:
\nDaridorexant can impair daytime wakefulness. Patients should be warned not to drive or engage in other activities requiring complete mental alertness if they feel drowsy the next day.
\nComplex Sleep Behaviors:
\nComplex sleep behaviors, including sleep-walking, sleep-driving, and engaging in other activities while not fully awake (e.g., preparing and eating food, making phone calls, having sex), have been reported. Discontinue immediately if a patient experiences a complex sleep behavior.
\nWorsening of Depression and Suicidal Ideation:
\nWorsening of depression and suicidal thoughts or actions have been reported. Monitor for these symptoms.
\nSleep Paralysis, Hypnagogic\/Hypnopompic Hallucinations, and Cataplexy-like Symptoms:
\nPatients may experience an inability to move or speak for up to several minutes during sleep-wake transitions, or experience vivid and disturbing perceptions.
\nRespiratory Depression:
\nConsider the potential for respiratory depression in patients with compromised respiratory function (e.g., COPD, Obstructive Sleep Apnea).
\n5. Adverse Reactions
\nMost Common:
\nHeadache, somnolence\/fatigue, and dizziness.
\n6. Drug Interactions
\nCNS Depressants:
\nConcomitant use with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) may increase the risk of CNS depression. Avoid use with alcohol.
\nCYP3A4 Inhibitors:
\nStrong CYP3A4 inhibitors (e.g., itraconazole): Avoid concomitant use.
\nModerate CYP3A4 inhibitors (e.g., diltiazem): Reduce the dose of daridorexant to 25 mg.
\nCYP3A4 Inducers:
\nAvoid concomitant use with strong or moderate CYP3A4 inducers (e.g., rifampin, carbamazepine) as they may decrease the efficacy of daridorexant.
\n7. Pharmaceutical Information
\nChemical Name:
\n2-(2,5-Dimethylpyrazin-3-yl)-5-methoxy-N-[(2S)-2-methyl-2,3-dihydro-1,4-benzoxazin-4-yl]pyrimidin-4-amine hydrochloride.
\nStorage:
\nStore at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted between 15\u00b0C and 30\u00b0C (59\u00b0F and 86\u00b0F).<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u79d1\u552f\u53ef\u00ae (Quviviq\u00ae)
\nGeneric Name: Daridorexant Hydrochloride
\nStrength: 50 mg per tablet, 20 tablets per box
\nManufacturer: Farmea
\nMarketing Authorization Holder: Idorsia Pharmaceuticals Ltd\uff1b\u5883\u5185\u6301\u8bc1\u4f01\u4e1a\uff1a\u6d77\u5357\u5148\u58f0\u836f\u4e1a\u6709\u9650\u516c\u53f8\uff08\u5148\u58f0\u836f\u4e1a Simcere\uff09
\nApproval Date in China: June 17, 2025
\nRegistration Number: \u56fd\u836f\u51c6\u5b57 HJ20250073
\nStorage: Store at 20\u201325\u2103, short-term storage allowed between 15\u201330\u2103; keep sealed, protected from light and moisture, and stored out of reach of children<\/p>\n
Price&Cost:Contact Us now for the best price of Daridorexant Hydrochloride\uff08Quviviq\uff09<\/p>\n","protected":false},"featured_media":3146,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[27],"product_tag":[],"class_list":["post-3144","product","type-product","status-publish","has-post-thumbnail","product_cat-tablets","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n